<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30291251</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2056-676X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Oct</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Disease primers</Title>
          <ISOAbbreviation>Nat Rev Dis Primers</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Testicular cancer.</ArticleTitle>
        <Pagination>
          <StartPage>29</StartPage>
          <MedlinePgn>29</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41572-018-0029-0</ELocationID>
        <Abstract>
          <AbstractText>Testicular cancer is the most common malignancy among men between 14 and 44 years of age, and its incidence has risen over the past two decades in Western countries. Both genetic and environmental factors contribute to the development of testicular cancer, for which cryptorchidism is the most common risk factor. Progress has been made in our understanding of the disease since the initial description of carcinoma in situ of the testis in 1972 (now referred to as germ cell neoplasia in situ), which has led to improved treatment options. The combination of surgery and cisplatin-based chemotherapy has resulted in a cure rate of &gt;90% in patients with testicular cancer, although some patients become refractory to chemotherapy or have a late relapse; an improved understanding of the molecular determinants underlying tumour sensitivity and resistance may lead to the development of novel therapies for these patients. This Primer provides an overview of the biology, epidemiology, diagnosis and current treatment guidelines for testicular cancer, with a focus on germ cell tumours. We also outline areas for future research and what to expect in the next decade for testicular cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Pathology and Laboratory Medicine and Urology, Indiana University School of Medicine, Indianapolis, IN, USA. lcheng@iupui.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Albers</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Heinrich-Heine University, Medical Faculty, Düsseldorf, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berney</LastName>
            <ForeName>Daniel M</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Oncology, Barts Cancer Institute, St Bartholomew's Hospital, Queen Mary University of London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feldman</LastName>
            <ForeName>Darren R</ForeName>
            <Initials>DR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Weill Cornell Medical College, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Daugaard</LastName>
            <ForeName>Gedske</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gilligan</LastName>
            <ForeName>Timothy</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Looijenga</LastName>
            <ForeName>Leendert H J</ForeName>
            <Initials>LHJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Josephine Nefkens Building, Erasmus MC-University Medical Center, Cancer Institute, Rotterdam, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Rev Dis Primers</MedlineTA>
        <NlmUniqueID>101672103</NlmUniqueID>
        <ISSNLinking>2056-676X</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C538105">Pallister Killian syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025063" MajorTopicYN="N">Chromosome Disorders</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002881" MajorTopicYN="N">Chromosomes, Human, Pair 12</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013736" MajorTopicYN="N">Testicular Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30291251</ArticleId>
        <ArticleId IdType="doi">10.1038/s41572-018-0029-0</ArticleId>
        <ArticleId IdType="pii">10.1038/s41572-018-0029-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel, R. L., Miller, K. D. &amp; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21442</ArticleId>
            <ArticleId IdType="pubmed">29313949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghazarian, A. A., Kelly, S. P., Altekruse, S. F., Rosenberg, P. S. &amp; McGlynn, K. A. Future of testicular germ cell tumor incidence in the United States: forecast through 2026. Cancer 123, 2320–2328 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.30597</ArticleId>
            <ArticleId IdType="pubmed">28241106</ArticleId>
            <ArticleId IdType="pmc">5629636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trabert, B., Chen, J., Devesa, S. S., Bray, F. &amp; McGlynn, K. A. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973–2007. Andrology 3, 4–12 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/andr.293</ArticleId>
            <ArticleId IdType="pubmed">25331326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitzmaurice, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 3, 524–548 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2017.1747</ArticleId>
            <ArticleId IdType="pubmed">27918777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skakkebaek, N. Possible carcinoma-in-situ of the testis. Lancet 300, 516–517 (1972).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(72)91909-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berney, D. M. et al. Germ cell neoplasia in situ (GCNIS): evolution of the current nomenclature for testicular pre-invasive germ cell malignancy. Histopathology 69, 7–10 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.12958</ArticleId>
            <ArticleId IdType="pubmed">26918959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E. &amp; Ulbright, T. M. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur. Urol. 70, 93–105 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2016.02.029</ArticleId>
            <ArticleId IdType="pubmed">26935559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moch, H., Humphrey, P. A., Ulbright, T. M. &amp; Reuter, V. E. in WHO Classification of Tumours of the Urinary System and Male e Genital Organs 4th edn (eds Moch, H. &amp; Ulbright, T. M.) (International Agency for Research on Cancer (IARC), 2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Oosterhuis, J. W. &amp; Looijenga, L. H. Testicular germ-cell tumours in a broader perspective. Nat. Rev. Cancer 5, 210–222 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng, L., Lyu, B. &amp; Roth, L. M. Perspectives on testicular germ cell neoplasms. Hum. Pathol. 59, 10–25 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humpath.2016.08.002</ArticleId>
            <ArticleId IdType="pubmed">27569298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albers, P. et al. Guidelines on testicular cancer: 2015 update. Eur. Urol. 68, 1054–1068 (2015). This paper presents the European Association of Urology guidelines on the treatment of testicular cancer.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2015.07.044</ArticleId>
            <ArticleId IdType="pubmed">26297604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oldenburg, J. et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24 (Suppl. 6), vi125–vi132 (2013). This paper presents the European Society for Medical Oncology guidelines on the management of testicular cancer.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24078656</ArticleId>
            <ArticleId IdType="pmc">24078656</ArticleId>
            <ArticleId IdType="doi">10.1093/annonc/mdt304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanna, N. H. &amp; Einhorn, L. H. Testicular cancer —discoveries and updates. N. Engl. J. Med. 371, 2005–2016 (2014). This is a comprehensive state of the art review on testicular cancer.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1407550</ArticleId>
            <ArticleId IdType="pubmed">25409373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanna, N. &amp; Einhorn, L. H. Testicular cancer: a reflection on 50 years of discovery. J. Clin. Oncol. 32, 3085–3092 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2014.56.0896</ArticleId>
            <ArticleId IdType="pubmed">25024068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandstad, T. et al. Practice makes perfect: the rest of the story in testicular cancer as a model curable neoplasm. J. Clin. Oncol. 35, 3525–3528 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.73.4723</ArticleId>
            <ArticleId IdType="pubmed">28854068</ArticleId>
            <ArticleId IdType="pmc">5791831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman, D. R., Bosl, G. J., Sheinfeld, J. &amp; Motzer, R. J. Medical treatment of advanced testicular cancer. Jama 299, 672–684 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.299.6.672</ArticleId>
            <ArticleId IdType="pubmed">18270356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chovanec, M., Hanna, N., Cary, K. C., Einhorn, L. &amp; Albany, C. Management of stage I testicular germ cell tumours. Nat. Rev. Urol. 13, 663–673 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrurol.2016.164</ArticleId>
            <ArticleId IdType="pubmed">27618772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fung, C. et al. Multi-institutional assessment of adverse health outcomes among North American testicular cancer survivors after modern cisplatin-based chemotherapy. J. Clin. Oncol. 35, 1211–1222 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.70.3108</ArticleId>
            <ArticleId IdType="pubmed">28240972</ArticleId>
            <ArticleId IdType="pmc">5455601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerns, S. L., Fung, C., Monahan, P. O., Ardeshir-Rouhani-Fard, S. &amp; Abu Zaid, M. I. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J. Clin. Oncol. 36, 1505–1512 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.0735</ArticleId>
            <ArticleId IdType="pubmed">29617189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology Testicular Cancer (version 2.2018) (NCCN, 2018).</Citation>
        </Reference>
        <Reference>
          <Citation>International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 15, 594–603 (1997). This is the first publication of the International Germ Cell Cancer Collaborative Group risk stratification system.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1997.15.2.594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amin, M. et al. (eds) AJCC Cancer Staging Manual. 8th edn (Springer, New York, 2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–386 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29210</ArticleId>
            <ArticleId IdType="pubmed">25220842</ArticleId>
            <ArticleId IdType="pmc">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay, J. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer http://globocan.iarc.fr (2013).</Citation>
        </Reference>
        <Reference>
          <Citation>Znaor, A., Lortet-Tieulent, J., Jemal, A. &amp; Bray, F. International variations and trends in testicular cancer incidence and mortality. Eur. Urol. 65, 1095–1106 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2013.11.004</ArticleId>
            <ArticleId IdType="pubmed">24268506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghazarian, A. A., Trabert, B., Devesa, S. S. &amp; McGlynn, K. A. Recent trends in the incidence of testicular germ cell tumors in the United States. Andrology 3, 13–18 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/andr.288</ArticleId>
            <ArticleId IdType="pubmed">25331158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daugaard, G. et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J. Clin. Oncol. 32, 3817–3823 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2013.53.5831</ArticleId>
            <ArticleId IdType="pubmed">25267754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortensen, M. S. et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur. Urol. 66, 1172–1178 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2014.07.001</ArticleId>
            <ArticleId IdType="pubmed">25064686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kier, M. G. et al. Prognostic factors and treatment results after bleomycin, etoposide, and cisplatin in germ cell cancer: a population-based study. Eur. Urol. 71, 290–298 (2017). This paper details a re-evaluation of prognostic factors for outcome and estimated survival in a Danish population-based cohort of 1,889 patients with testicular cancer treated with standard chemotherapy.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2016.09.015</ArticleId>
            <ArticleId IdType="pubmed">27649970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Purdue, M. P., Devesa, S. S., Sigurdson, A. J. &amp; McGlynn, K. A. International patterns and trends in testis cancer incidence. Int. J. Cancer 115, 822–827 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.20931</ArticleId>
            <ArticleId IdType="pubmed">15704170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bray, F. et al. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int. J. Cancer 118, 3099–3111 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.21747</ArticleId>
            <ArticleId IdType="pubmed">16395710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lymperi, S. &amp; Giwercman, A. Endocrine disruptors and testicular function. Metabolism 86, 79–90 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.metabol.2018.03.022</ArticleId>
            <ArticleId IdType="pubmed">29605435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skakkebaek, N. E., Rajpert-De Meyts, E. &amp; Main, K. M. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum. Reprod. 16, 972–978 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humrep/16.5.972</ArticleId>
            <ArticleId IdType="pubmed">11331648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemminki, K. &amp; Li, X. Cancer risks in Nordic immigrants and their offspring in Sweden. Eur. J. Cancer 38, 2428–2434 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0959-8049(02)00496-3</ArticleId>
            <ArticleId IdType="pubmed">12460788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannandrea, F. &amp; Fargnoli, S. Environmental factors affecting growth and occurrence of testicular cancer in childhood: an overview of the current epidemiological evidence. Children 4, 1 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/children4010001</ArticleId>
            <ArticleId IdType="pmc">5296662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurney, J. K., Stanley, J., Shaw, C. &amp; Sarfati, D. Ethnic patterns of hypospadias in New Zealand do not resemble those observed for cryptorchidism and testicular cancer: evidence of differential aetiology? Andrology 4, 82–86 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/andr.12121</ArticleId>
            <ArticleId IdType="pubmed">26566182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonde, J. P. et al. The epidemiologic evidence linking prenatal and postnatal exposure to endocrine disrupting chemicals with male reproductive disorders: a systematic review and meta-analysis. Hum. Reprod. Update 23, 104–125 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humupd/dmw036</ArticleId>
            <ArticleId IdType="pubmed">27655588</ArticleId>
            <ArticleId IdType="pmc">5155570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Litchfield, K. et al. Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nat. Genet. 49, 1133–1140 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3896</ArticleId>
            <ArticleId IdType="pubmed">28604728</ArticleId>
            <ArticleId IdType="pmc">6016736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mucci, L. A. et al. Familial risk and heritability of cancer among twins in nordic countries. JAMA 315, 68–76 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2015.17703</ArticleId>
            <ArticleId IdType="pubmed">26746459</ArticleId>
            <ArticleId IdType="pmc">5498110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Czene, K., Lichtenstein, P. &amp; Hemminki, K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. Int. J. Cancer 99, 260–266 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.10332</ArticleId>
            <ArticleId IdType="pubmed">11979442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampson, J. N. et al. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types. J. Natl Cancer Inst. 107, 279 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djv279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong, C. &amp; Hemminki, K. Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families. Int. J. Cancer 92, 144–150 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0215(200102)9999:9999&lt;::AID-IJC1147&gt;3.0.CO;2-C</ArticleId>
            <ArticleId IdType="pubmed">11279618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westergaard, T. et al. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study. Int. J. Cancer 66, 627–631 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-0215(19960529)66:5&lt;627::AID-IJC8&gt;3.0.CO;2-V</ArticleId>
            <ArticleId IdType="pubmed">8647624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gundy, S., Babosa, M., Baki, M. &amp; Bodrogi, I. Increased predisposition to cancer in brothers and offspring of testicular tumor patients. Pathol. Oncol. Res. 10, 197–203 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03033760</ArticleId>
            <ArticleId IdType="pubmed">15619639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemminki, K. &amp; Chen, B. Familial risks in testicular cancer as aetiological clues. Int. J. Androl 29, 205–210 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2605.2005.00599.x</ArticleId>
            <ArticleId IdType="pubmed">16466541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson, R. E. et al. Cancer risk in first- and second-degree relatives of men with poor semen quality. Fertil. Steril. 106, 731–738 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2016.05.021</ArticleId>
            <ArticleId IdType="pubmed">27336212</ArticleId>
            <ArticleId IdType="pmc">5617641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kier, M. G. et al. Second malignant neoplasms and cause of death in patients with germ cell cancer: a danish nationwide cohort study. JAMA Oncol. 2, 1624–1627 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.3651</ArticleId>
            <ArticleId IdType="pubmed">27711914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fossa, S. D. et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J. Natl Cancer Inst. 97, 1056–1066 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/dji185</ArticleId>
            <ArticleId IdType="pubmed">16030303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang, W. W., Kobayashi, T., Irie, N., Dietmann, S. &amp; Surani, M. A. Specification and epigenetic programming of the human germ line. Nat. Rev. Genet. 17, 585–600 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg.2016.88</ArticleId>
            <ArticleId IdType="pubmed">27573372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rijlaarsdam, M. A. &amp; Looijenga, L. H. An oncofetal and developmental perspective on testicular germ cell cancer. Semin. Cancer Biol. 29, 59–74 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2014.07.003</ArticleId>
            <ArticleId IdType="pubmed">25066859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang, C., Berney, D. M., Hirsch, M. S., Cheng, L. &amp; Ulbright, T. M. Evidence supporting the existence of benign teratomas of the postpubertal testis: a clinical, histopathologic, and molecular genetic analysis of 25 cases. Am. J. Surg. Pathol. 37, 827–835 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e31827dcc4c</ArticleId>
            <ArticleId IdType="pubmed">23598964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oosterhuis, J. W. et al. Pediatric germ cell tumors presenting beyond childhood? Andrology 3, 70–77 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/andr.305</ArticleId>
            <ArticleId IdType="pubmed">25427839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sievers, S. et al. IGF2/H19 imprinting analysis of human germ cell tumors (GCTs) using the methylation-sensitive single-nucleotide primer extension method reflects the origin of GCTs in different stages of primordial germ cell development. Genes Chromosomes Cancer 44, 256–264 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.20237</ArticleId>
            <ArticleId IdType="pubmed">16001432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herszfeld, D. et al. CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat. Biotechnol. 24, 351–357 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt1197</ArticleId>
            <ArticleId IdType="pubmed">16501577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fustino, N., Rakheja, D., Ateek, C. S., Neumann, J. C. &amp; Amatruda, J. F. Bone morphogenetic protein signalling activity distinguishes histological subsets of paediatric germ cell tumours. Int. J. Androl 34, e218–e233 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2605.2011.01186.x</ArticleId>
            <ArticleId IdType="pubmed">21696393</ArticleId>
            <ArticleId IdType="pmc">4129369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amatruda, J. F. et al. DNA methylation analysis reveals distinct methylation signatures in pediatric germ cell tumors. BMC Cancer 13, 313 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-13-313</ArticleId>
            <ArticleId IdType="pubmed">23806198</ArticleId>
            <ArticleId IdType="pmc">3701494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youngren, K. K. et al. The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. Nature 435, 360–364 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature03595</ArticleId>
            <ArticleId IdType="pubmed">15902260</ArticleId>
            <ArticleId IdType="pmc">1421521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heaney, J. D., Lam, M. Y., Michelson, M. V. &amp; Nadeau, J. H. Loss of the transmembrane but not the soluble kit ligand isoform increases testicular germ cell tumor susceptibility in mice. Cancer Res. 68, 5193–5197 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-0779</ArticleId>
            <ArticleId IdType="pubmed">18593919</ArticleId>
            <ArticleId IdType="pmc">2562736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nemark, A. I., Mazyrko, A. V. &amp; Astakhov Iu, I. Use of plasmapheresis in multimodality correction of hemostasis disorders in patients with calculous pyelonephritis. Ter. Arkh. 61, 86–88 (1989).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2799724</ArticleId>
            <ArticleId IdType="pmc">2799724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Looijenga, L. H., Stoop, H. &amp; Biermann, K. Testicular cancer: biology and biomarkers. Virchows Arch. 464, 301–313 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00428-013-1522-1</ArticleId>
            <ArticleId IdType="pubmed">24487784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mostert, M. et al. Comparative genomic and in situ hybridization of germ cell tumors of the infantile testis. Lab. Invest. 80, 1055–1064 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.3780110</ArticleId>
            <ArticleId IdType="pubmed">10908150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider, D. T. et al. Genetic analysis of mediastinal nonseminomatous germ cell tumors in children and adolescents. Genes Chromosomes Cancer 34, 115–125 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.10053</ArticleId>
            <ArticleId IdType="pubmed">11921289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider, D. T. et al. Genetic analysis of childhood germ cell tumors with comparative genomic hybridization. Klin. Padiatr. 213, 204–211 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-2001-16852</ArticleId>
            <ArticleId IdType="pubmed">11528555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>[No authors listed.] Molecular mechanisms of neuronal responsiveness. Proceedings of a symposium. March 21–23,1986, Burlington, Vermont. Adv. Exp. Med. Biol. 221, 1–563 (1987).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4684-7618-7_1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frazier, A. L. et al. Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. J. Clin. Oncol. 33, 195–201 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2014.58.3369</ArticleId>
            <ArticleId IdType="pubmed">25452439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray, M. J. et al. A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. Br. J. Cancer 114, 151–162 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2015.429</ArticleId>
            <ArticleId IdType="pubmed">26671749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honecker, F. et al. Germ cell lineage differentiation in non-seminomatous germ cell tumours. J. Pathol. 208, 395–400 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.1872</ArticleId>
            <ArticleId IdType="pubmed">16273510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajpert-De Meyts, E., Nielsen, J. E., Skakkebaek, N. E. &amp; Almstrup, K. Diagnostic markers for germ cell neoplasms: from placental-like alkaline phosphatase to micro-RNAs. Folia Histochem. Cytobiol. 53, 177–188 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/FHC.a2015.0020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Jong, J. et al. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. J. Pathol. 215, 21–30 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2332</ArticleId>
            <ArticleId IdType="pubmed">18348160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irie, N. et al. SOX17 is a critical specifier of human primordial germ cell fate. Cell 160, 253–268 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.12.013</ArticleId>
            <ArticleId IdType="pubmed">25543152</ArticleId>
            <ArticleId IdType="pmc">4310934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonne, S. B. et al. Analysis of SOX2 expression in developing human testis and germ cell neoplasia. Int. J. Dev. Biol. 54, 755–760 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1387/ijdb.082668ss</ArticleId>
            <ArticleId IdType="pubmed">19876845</ArticleId>
            <ArticleId IdType="pmc">3556811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klaassen, Z. et al. Clinical disparities for minorities and foreign-born men with undescended versus descended testicular germ cell tumors. Clin. Genitourin. Cancer 14, e251–e255 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clgc.2015.08.004</ArticleId>
            <ArticleId IdType="pubmed">26428610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Graaff, W. E. et al. Ploidy of testicular carcinoma in situ. Lab. Invest. 66, 166–168 (1992).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1310514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Killian, J. K. et al. Imprints and DPPA3 are bypassed during pluripotency- and differentiation-coupled methylation reprogramming in testicular germ cell tumors. Genome Res. 26, 1490–1504 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gr.201293.115</ArticleId>
            <ArticleId IdType="pubmed">27803193</ArticleId>
            <ArticleId IdType="pmc">5088592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Echten, J. et al. No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testis. Genes Chromosomes Cancer 14, 133–144 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.2870140208</ArticleId>
            <ArticleId IdType="pubmed">8527395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malek, N. P. et al. Quantification of additional short arms of chromosome 12 in germ cell tumours using the polymerase chain reaction. Eur. J. Cancer 33, 1488–1494 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0959-8049(97)00152-4</ArticleId>
            <ArticleId IdType="pubmed">9337694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews, P. W. et al. Assessing the safety of human pluripotent stem cells and their derivatives for clinical applications. Stem Cell Rep. 9, 1–4 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stemcr.2017.05.029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Looijenga, L. H., Gillis, A. J., van Gurp, R. J., Verkerk, A. J. &amp; Oosterhuis, J. W. X inactivation in human testicular tumors. XIST expression and androgen receptor methylation status. Am. J. Pathol. 151, 581–590 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1858006</ArticleId>
            <ArticleId IdType="pmc">1858006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawakami, T., Okamoto, K., Ogawa, O. &amp; Okada, Y. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet 363, 40–42 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(03)15170-7</ArticleId>
            <ArticleId IdType="pubmed">14723995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Litchfield, K. et al. Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nat. Commun. 6, 5973 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms6973</ArticleId>
            <ArticleId IdType="pubmed">25609015</ArticleId>
            <ArticleId IdType="pmc">4338546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cutcutache, I. et al. Exome-wide sequencing shows low mutation rates and identifies novel mutated genes in seminomas. Eur. Urol. 68, 77–83 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2014.12.040</ArticleId>
            <ArticleId IdType="pubmed">25597018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Litchfield, K. et al. Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility. Nat. Commun. 7, 13840 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms13840</ArticleId>
            <ArticleId IdType="pubmed">27996046</ArticleId>
            <ArticleId IdType="pmc">5187424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bagrodia, A. et al. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. J. Clin. Oncol. 34, 4000–4007 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.68.7798</ArticleId>
            <ArticleId IdType="pubmed">27646943</ArticleId>
            <ArticleId IdType="pmc">5477828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kersemaekers, A. M. et al. Role of P53 and MDM2 in treatment response of human germ cell tumors. J. Clin. Oncol. 20, 1551–1561 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2002.20.6.1551</ArticleId>
            <ArticleId IdType="pubmed">11896104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor-Weiner, A. et al. Genomic evolution and chemoresistance in germ-cell tumours. Nature 540, 114–118 (2016). This study reports genomic features that are associated with the origin and the evolution of testicular cancer.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature20596</ArticleId>
            <ArticleId IdType="pubmed">27905446</ArticleId>
            <ArticleId IdType="pmc">5553306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voorhoeve, P. M. et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124, 1169–1181 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.02.037</ArticleId>
            <ArticleId IdType="pubmed">16564011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gillis, A. J. et al. High-throughput microRNAome analysis in human germ cell tumours. J. Pathol. 213, 319–328 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2230</ArticleId>
            <ArticleId IdType="pubmed">17893849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rijlaarsdam, M. A. et al. Identification of known and novel germ cell cancer-specific (embryonic) miRs in serum by high-throughput profiling. Andrology 3, 85–91 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/andr.298</ArticleId>
            <ArticleId IdType="pubmed">25382245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novotny, G. W. et al. MicroRNA expression profiling of carcinoma in situ cells of the testis. Endocr. Relat. Cancer 19, 365–379 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-11-0271</ArticleId>
            <ArticleId IdType="pubmed">22420006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmer, R. D. et al. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 70, 2911–2923 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-3301</ArticleId>
            <ArticleId IdType="pubmed">20332240</ArticleId>
            <ArticleId IdType="pmc">3000593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, N., Long, B., Han, W., Yuan, S. &amp; Wang, K. microRNAs: important regulators of stem cells. Stem Cell Res. Ther. 8, 110 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13287-017-0551-0</ArticleId>
            <ArticleId IdType="pubmed">28494789</ArticleId>
            <ArticleId IdType="pmc">5426004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radtke, A. et al. The novel biomarker of germ cell tumours, micro-RNA-371a-3p, has a very rapid decay in patients with clinical stage 1. Urol. Int. 100, 470–475 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000488771</ArticleId>
            <ArticleId IdType="pubmed">29698973</ArticleId>
            <ArticleId IdType="pmc">6039090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dieckmann, K. P. et al. Testicular germ-cell tumours: a descriptive analysis of clinical characteristics at first presentation. Urol. Int. 100, 409–419 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000488284</ArticleId>
            <ArticleId IdType="pubmed">29649815</ArticleId>
            <ArticleId IdType="pmc">6039091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leao, R. et al. Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor. J. Urol. 200, 126–135 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.juro.2018.02.068</ArticleId>
            <ArticleId IdType="pubmed">29474847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray, M. J. et al. Identification of microRNAs from the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am. J. Clin. Pathol. 135, 119–125 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/AJCPOE11KEYZCJHT</ArticleId>
            <ArticleId IdType="pubmed">21173133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belge, G., Dieckmann, K. P., Spiekermann, M., Balks, T. &amp; Bullerdiek, J. Serum levels of microRNAs miR-371-3: a novel class of serum biomarkers for testicular germ cell tumors? Eur. Urol. 61, 1068–1069 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2012.02.037</ArticleId>
            <ArticleId IdType="pubmed">22386195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dieckmann, K. P. et al. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br. J. Cancer 107, 1754–1760 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2012.469</ArticleId>
            <ArticleId IdType="pubmed">23059743</ArticleId>
            <ArticleId IdType="pmc">3493876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gillis, A. J. et al. Targeted serum miRNA (TsmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. Mol. Oncol. 7, 1083–1092 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2013.08.002</ArticleId>
            <ArticleId IdType="pubmed">24012110</ArticleId>
            <ArticleId IdType="pmc">5528443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spiekermann, M. et al. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker. Andrology 3, 78–84 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.2047-2927.2014.00269.x</ArticleId>
            <ArticleId IdType="pubmed">25187505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spiekermann, M., Dieckmann, K. P., Balks, T., Bullerdiek, J. &amp; Belge, G. Is relative quantification dispensable for the measurement of microRNAs as serum biomarkers in germ cell tumors? Anticancer Res. 35, 117–121 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25550541</ArticleId>
            <ArticleId IdType="pmc">25550541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dieckmann, K. P. et al. MicroRNA miR-371a-3p-A novel serum biomarker of testicular germ cell tumors: evidence for specificity from measurements in testicular vein blood and in neoplastic hydrocele fluid. Urol. Int. 97, 76–83 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000444303</ArticleId>
            <ArticleId IdType="pubmed">26989896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Agthoven, T. &amp; Looijenga, L. H. Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test). Oncotarget 8, 58037–58049 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28938535</ArticleId>
            <ArticleId IdType="pmc">28938535</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.10867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Agthoven, T., Eijkenboom, W. M. H. &amp; Looijenga, L. H. J. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients. Cell. Oncol. 40, 379–388 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13402-017-0333-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beyer, J. et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann. Oncol. 24, 878–888 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mds579</ArticleId>
            <ArticleId IdType="pubmed">23152360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nathanson, K. L. et al. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am. J. Hum. Genet. 77, 1034–1043 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/498455</ArticleId>
            <ArticleId IdType="pubmed">16380914</ArticleId>
            <ArticleId IdType="pmc">1285161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanetsky, P. A. et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat. Genet. 41, 811–815 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.393</ArticleId>
            <ArticleId IdType="pubmed">19483682</ArticleId>
            <ArticleId IdType="pmc">2865677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapley, E. A. et al. A genome-wide association study of testicular germ cell tumor. Nat. Genet. 41, 807–810 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.394</ArticleId>
            <ArticleId IdType="pubmed">19483681</ArticleId>
            <ArticleId IdType="pmc">2871592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanetsky, P. A. et al. A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum. Mol. Genet. 20, 3109–3117 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddr207</ArticleId>
            <ArticleId IdType="pubmed">21551455</ArticleId>
            <ArticleId IdType="pmc">3131044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumacher, F. R. et al. Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Hum. Mol. Genet. 22, 2748–2753 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddt109</ArticleId>
            <ArticleId IdType="pubmed">23462292</ArticleId>
            <ArticleId IdType="pmc">3674801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung, C. C. et al. Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat. Genet. 45, 680–685 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2634</ArticleId>
            <ArticleId IdType="pubmed">3723930</ArticleId>
            <ArticleId IdType="pmc">3723930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koster, R. et al. Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors. Hum. Mol. Genet. 23, 6061–6068 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddu305</ArticleId>
            <ArticleId IdType="pubmed">4204765</ArticleId>
            <ArticleId IdType="pmc">4204765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang, J. et al. Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nat. Commun. 8, 15034 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms15034</ArticleId>
            <ArticleId IdType="pubmed">5414179</ArticleId>
            <ArticleId IdType="pmc">5414179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang, Z. et al. Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. Nat. Genet. 49, 1141–1147 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3879</ArticleId>
            <ArticleId IdType="pubmed">5490654</ArticleId>
            <ArticleId IdType="pmc">5490654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann, J. C. et al. Mutation in the type IB bone morphogenetic protein receptor Alk6b impairs germ-cell differentiation and causes germ-cell tumors in zebrafish. Proc. Natl Acad. Sci. USA 108, 13153–13158 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1102311108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oosterhuis, J. W. &amp; Looijenga, L. H. in Pathology and Biology of Human Germ Cell Tumors (eds Nogales, F. F. &amp; Jimenez, R. E.) 23–130 (Springer, 2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Mayer, F. et al. Aneuploidy of human testicular germ cell tumors is associated with amplification of centrosomes. Oncogene 22, 3859–3866 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1206469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeron-Medina, J. et al. A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection. Cell 155, 410–422 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.09.017</ArticleId>
            <ArticleId IdType="pubmed">4171736</ArticleId>
            <ArticleId IdType="pmc">4171736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannoulatou, E. et al. Whole-genome sequencing of spermatocytic tumors provides insights into the mutational processes operating in the male germline. PLOS ONE 12, e0178169 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0178169</ArticleId>
            <ArticleId IdType="pubmed">5439955</ArticleId>
            <ArticleId IdType="pmc">5439955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim, J. et al. OCT2, SSX and SAGE1 reveal the phenotypic heterogeneity of spermatocytic seminoma reflecting distinct subpopulations of spermatogonia. J. Pathol. 224, 473–483 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2919</ArticleId>
            <ArticleId IdType="pubmed">3210831</ArticleId>
            <ArticleId IdType="pmc">3210831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Looijenga, L. H. Spermatocytic seminoma: toward further understanding of pathogenesis. J. Pathol. 224, 431–433 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2939</ArticleId>
            <ArticleId IdType="pubmed">21725972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannoulatou, E. et al. Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline. Proc. Natl Acad. Sci. USA 110, 20152–20157 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1311381110</ArticleId>
            <ArticleId IdType="pubmed">24259709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim, J. et al. Selfish spermatogonial selection: evidence from an immunohistochemical screen in testes of elderly men. PLOS ONE 7, e42382 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0042382</ArticleId>
            <ArticleId IdType="pubmed">22879958</ArticleId>
            <ArticleId IdType="pmc">3412839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg, C. et al. Chromosomal constitution of human spermatocytic seminomas: comparative genomic hybridization supported by conventional and interphase cytogenetics. Genes Chromosomes Cancer 23, 286–291 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1098-2264(199812)23:4&lt;286::AID-GCC2&gt;3.0.CO;2-6</ArticleId>
            <ArticleId IdType="pubmed">9824200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Looijenga, L. H. et al. Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res. 66, 290–302 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-2936</ArticleId>
            <ArticleId IdType="pubmed">16397242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dieckmann, K. P., Frey, U. &amp; Lock, G. Contemporary diagnostic work-up of testicular germ cell tumours. Nat. Rev. Urol. 10, 703–712 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrurol.2013.254</ArticleId>
            <ArticleId IdType="pubmed">24217678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray, M. J., Huddart, R. A. &amp; Coleman, N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat. Rev. Urol. 13, 715–725 (2016). This is a comprehensive review of serum biomarker testing in the diagnosis and monitoring of testicular cancer.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrurol.2016.170</ArticleId>
            <ArticleId IdType="pubmed">27754472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhardwa, J. M. et al. Assessing the size and stage of testicular germ cell tumours: 1984–2003. BJU Int. 96, 819–821 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1464-410X.2005.05748.x</ArticleId>
            <ArticleId IdType="pubmed">16153209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matei, D. V. et al. Reliability of frozen section examination in a large cohort of testicular masses: what did we learn? Clin. Genitourin. Cancer. 15, e689–e696 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clgc.2017.01.012</ArticleId>
            <ArticleId IdType="pubmed">28216275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silverio, P. C., Schoofs, F., Iselin, C. E. &amp; Tille, J. C. Fourteen-year experience with the intraoperative frozen section examination of testicular lesion in a tertiary university center. Ann. Diagn. Pathol. 19, 99–102 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.anndiagpath.2014.12.006</ArticleId>
            <ArticleId IdType="pubmed">25747842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williamson, S. R. et al. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the international society of urological pathology testis consultation panel. Histopathology 70, 335–346 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henley, J. D., Young, R. H. &amp; Ulbright, T. M. Malignant sertoli cell tumors of the testis: a study of 13 examples of a neoplasm frequently misinterpreted as seminoma. Am. J. Surg. Pathol. 26, 541–550 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-200205000-00001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng, L. et al. OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J. Pathol. 211, 1–9 (2007). This is a comprehensive review on the discovery and application of diagnostic biomarkers.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulbright, T. M., Tickoo, S. K., Berney, D. M. &amp; Srigley, J. R. Best practices recommendations in the application of immunohistochemistry in testicular tumors: report from the International Society of Urological Pathology consensus conference. Am. J. Surg. Pathol. 38, e50–e59 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0000000000000233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng, L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer 101, 2006–2010 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.20566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berney, D. M., Lu, Y. J., Shamash, J. &amp; Idrees, M. Postchemotherapy changes in testicular germ cell tumours: biology and morphology. Histopathology 70, 26–39 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kum, J. B. et al. Molecular genetic evidence supporting the origin of somatic-type malignancy and teratoma from the same progenitor cell. Am. J. Surg. Pathol. 36, 1849–1856 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e31826df1ab</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>George, D. W. et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J. Clin. Oncol. 21, 113–122 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2003.03.019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortensen, M. S. et al. Late relapses in stage I testicular cancer patients on surveillance. Eur. Urol. 70, 365–371 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2016.03.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sobin, L. H., Gospodarowicz, M. K., Wittekind, C. (eds) UICC International Union Against Cancer: TNM Classification of Malalignant Tumours 7th edn (Wiley-Blackwell, Oxford, 2009).</Citation>
        </Reference>
        <Reference>
          <Citation>Gilligan, T. D. et al. American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J. Clin. Oncol. 28, 3388–3404 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.26.4481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warde, P. et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J. Clin. Oncol. 20, 4448–4452 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2002.01.038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung, P. et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med. 4, 155–160 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.324</ArticleId>
            <ArticleId IdType="pubmed">4312129</ArticleId>
            <ArticleId IdType="pmc">4312129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aparicio, J. et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann. Oncol. 25, 2173–2178 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdu437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamba, T. et al. Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int. J. Urol. 17, 980–987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1442-2042.2010.02645.x</ArticleId>
            <ArticleId IdType="pubmed">3017741</ArticleId>
            <ArticleId IdType="pmc">3017741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunphy, C. H., Ayala, A. G., Swanson, D. A., Ro, J. Y. &amp; Logothetis, C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer 62, 1202–1206 (1988).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0142(19880915)62:6&lt;1202::AID-CNCR2820620627&gt;3.0.CO;2-S</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daugaard, G. et al. Surgery after relapse in stage I nonseminomatous testicular cancer. J. Clin. Oncol. 33, 2322 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2014.60.2177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kollmannsberger, C. et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J. Clin. Oncol. 33, 51–57 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2014.56.2116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albers, P. et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J. Clin. Oncol. 21, 1505–1512 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2003.07.169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilbert, D. C. et al. Defining a new prognostic index for stage I nonseminomatous germ cell tumors using CXCL12 expression and proportion of embryonal carcinoma. Clin. Cancer Res. 22, 1265–1273 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wood, H. M. &amp; Elder, J. S. Cryptorchidism and testicular cancer: separating fact from fiction. J. Urol. 181, 452–461 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.juro.2008.10.074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orchid. Testicular cancer basics. Orchid https://orchid-cancer.org.uk/wp-content/uploads/2018/06/1050-Testicular-Cancer-Basics-Z-Card-2018-4.pdf (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Giwercman, A., Muller, J. &amp; Skakkebaek, N. E. Carcinoma in situ of the undescended testis. Semin. Urol. 6, 110–119 (1988).</Citation>
        </Reference>
        <Reference>
          <Citation>Skakkebaek, N. E., Berthelsen, J. G. &amp; Muller, J. Carcinoma-in-situ of the undescended testis. Urol. Clin. North Am. 9, 377–385 (1982).</Citation>
        </Reference>
        <Reference>
          <Citation>Skakkebaek, N. E., Berthelsen, J. G., Giwercman, A. &amp; Muller, J. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int. J. Androl 10, 19–28 (1987).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2605.1987.tb00161.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dieckmann, K. P. &amp; Loy, V. False-negative biopsies for the diagnosis of testicular intraepithelial neoplasia (TIN)—an update. Eur. Urol. 43, 516–521 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0302-2838(03)00101-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kier, M. G. et al. Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based study. Ann. Oncol. 26, 737–742 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdu585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swerdlow, A. J., Huttly, S. R. &amp; Smith, P. G. Testicular cancer and antecedent diseases. Br. J. Cancer 55, 97–103 (1987).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.1987.20</ArticleId>
            <ArticleId IdType="pubmed">2001571</ArticleId>
            <ArticleId IdType="pmc">2001571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kristianslund, S., Fossa, S. D. &amp; Kjellevold, K. Bilateral malignant testicular germ cell cancer. Br. J. Urol. 58, 60–63 (1986).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1464-410X.1986.tb05429.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dieckmann, K. P. &amp; Loy, V. The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: the recent German experience. APMIS 106, 13–20 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1699-0463.1998.tb01315.x</ArticleId>
            <ArticleId IdType="pubmed">9524558</ArticleId>
            <ArticleId IdType="pmc">9524558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones, T. D. et al. Screening for intratubular germ cell neoplasia of the testis using OCT4 immunohistochemistry. Am. J. Surg. Pathol. 30, 1427–1431 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.pas.0000213288.50660.f7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Zwan, Y. G., Biermann, K., Wolffenbuttel, K. P., Cools, M. &amp; Looijenga, L. H. Gonadal maldevelopment as risk factor for germ cell cancer: towards a clinical decision model. Eur. Urol. 67, 692–701 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2014.07.011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cools, M. et al. Malignant testicular germ cell tumors in postpubertal individuals with androgen insensitivity: prevalence, pathology and relevance of single nucleotide polymorphism-based susceptibility profiling. Hum. Reprod. 32, 2561–2573 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humrep/dex300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Travis, L. B. et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst. 97, 1354–1365 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/dji278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horwich, A. et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br. J. Cancer 110, 256–263 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliver, R. T. et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366, 293–300 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)66984-X</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliver, R. T. et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J. Clin. Oncol. 29, 957–962 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.26.4655</ArticleId>
            <ArticleId IdType="pubmed">21282539</ArticleId>
            <ArticleId IdType="pmc">21282539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer, S. et al. Outcome of men with relapse after adjuvant carboplatin for clinical stage I seminoma. J. Clin. Oncol. 35, 194–200 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.69.0958</ArticleId>
            <ArticleId IdType="pubmed">27893332</ArticleId>
            <ArticleId IdType="pmc">27893332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandstad, T. et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann. Oncol. 27, 1299–1304 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw164</ArticleId>
            <ArticleId IdType="pubmed">27052649</ArticleId>
            <ArticleId IdType="pmc">27052649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosni, A. et al. Clinical characteristics and outcomes of late relapse in stage I testicular seminoma. Clin. Oncol. 28, 648–654 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clon.2016.06.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nayan, M. et al. Conditional risk of relapse in surveillance for clinical stage I testicular cancer. Eur. Urol. 71, 120–127 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2016.07.013</ArticleId>
            <ArticleId IdType="pubmed">27527805</ArticleId>
            <ArticleId IdType="pmc">27527805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boormans, J. L. et al. Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a systematic review by the Testicular Cancer Guidelines Panel. Eur. Urol. 73, 394–405 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2017.09.025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lago-Hernandez, C. A. et al. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann. Oncol. 26, 1396–1401 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25888612</ArticleId>
            <ArticleId IdType="pmc">25888612</ArticleId>
            <ArticleId IdType="doi">10.1093/annonc/mdv180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albers, P. et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J. Clin. Oncol. 26, 2966–2972 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.12.0899</ArticleId>
            <ArticleId IdType="pubmed">18458040</ArticleId>
            <ArticleId IdType="pmc">18458040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandstad, T. et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J. Clin. Oncol. 27, 2122–2128 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2008.18.8953</ArticleId>
            <ArticleId IdType="pubmed">19307506</ArticleId>
            <ArticleId IdType="pmc">19307506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Classen, J. et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J. Clin. Oncol. 21, 1101–1106 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2003.06.065</ArticleId>
            <ArticleId IdType="pubmed">12637477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidberger, H. et al. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int. J. Radiat. Oncol. Biol. Phys. 39, 321–326 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0360-3016(97)00155-7</ArticleId>
            <ArticleId IdType="pubmed">9308934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-del-Muro, X. et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J. Clin. Oncol. 26, 5416–5421 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.15.9103</ArticleId>
            <ArticleId IdType="pubmed">18936476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winter, C., Raman, J. D., Sheinfeld, J. &amp; Albers, P. Retroperitoneal lymph node dissection after chemotherapy. BJU Int. 104, 1404–1412 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1464-410X.2009.08867.x</ArticleId>
            <ArticleId IdType="pubmed">19840021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donohue, J. P. Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT). Urol. Oncol. 21, 129–132 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1078-1439(02)00212-0</ArticleId>
            <ArticleId IdType="pubmed">12856641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donohue, J. P. &amp; Foster, R. S. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol. Clin. North Am. 25, 461–468 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0094-0143(05)70035-5</ArticleId>
            <ArticleId IdType="pubmed">9728215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wymer, K. M. et al. Adherence to National Comprehensive Cancer Network(R) guidelines for testicular cancer. J. Urol. 197, 684–689 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.juro.2016.09.073</ArticleId>
            <ArticleId IdType="pubmed">27663460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feuer, E. J. et al. After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J. Clin. Oncol. 12, 368–377 (1994).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1994.12.2.368</ArticleId>
            <ArticleId IdType="pubmed">7509384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Wit, R. et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br. J. Cancer 71, 1311–1314 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.1995.254</ArticleId>
            <ArticleId IdType="pubmed">7540039</ArticleId>
            <ArticleId IdType="pmc">2033818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Culine, S. et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J. Clin. Oncol. 26, 421–427 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.13.8461</ArticleId>
            <ArticleId IdType="pubmed">18202419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cullen, M. et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N. Engl. J. Med. 353, 988–998 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa050078</ArticleId>
            <ArticleId IdType="pubmed">16148284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fizazi, K. et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 15, 1442–1450 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)70490-5</ArticleId>
            <ArticleId IdType="pubmed">25456363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer, R. J. et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J. Clin. Oncol. 15, 2546–2552 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1997.15.7.2546</ArticleId>
            <ArticleId IdType="pubmed">9215823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman, D. R. et al. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options—an analysis from the global germ cell cancer group. J. Clin. Oncol. 34, 345–351 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.62.7000</ArticleId>
            <ArticleId IdType="pubmed">26460295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doyle, D. M. &amp; Einhorn, L. H. Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int. J. Radiat. Oncol. Biol. Phys. 70, 1361–1364 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijrobp.2007.11.005</ArticleId>
            <ArticleId IdType="pubmed">18374223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng, L. et al. Molecular genetic evidence supporting the neoplastic nature of fibrous stroma in testicular teratoma. Mod. Pathol. 25, 1432–1438 (2012). This study provides evidence that both epithelial and fibrous components of teratomas are derived from a common progenitor. Fibrous stroma (fibrosis) after chemotherapy is neoplastic.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2012.99</ArticleId>
            <ArticleId IdType="pubmed">22684226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandli, D. W. et al. Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Res. 63, 6063–6068 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14522936</ArticleId>
            <ArticleId IdType="pmc">14522936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng, L. et al. Molecular genetic evidence supporting the neoplastic nature of stromal cells in ‘fibrosis’ after chemotherapy for testicular germ cell tumours. J. Pathol. 213, 65–71 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2202</ArticleId>
            <ArticleId IdType="pubmed">17634958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehrlich, Y., Brames, M. J., Beck, S. D., Foster, R. S. &amp; Einhorn, L. H. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J. Clin. Oncol. 28, 531–536 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.23.0714</ArticleId>
            <ArticleId IdType="pubmed">20026808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kollmannsberger, C. et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J. Clin. Oncol. 28, 537–542 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.23.0755</ArticleId>
            <ArticleId IdType="pubmed">20026807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lakes, J., Lusch, A., Nini, A. &amp; Albers, P. Retroperitoneal lymph node dissection in the setting of elevated markers. Curr. Opin. Urol. 28, 435–439 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30004909</ArticleId>
            <ArticleId IdType="pmc">30004909</ArticleId>
            <ArticleId IdType="doi">10.1097/MOU.0000000000000535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winter, C. et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur. Urol. 61, 403–409 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2011.10.045</ArticleId>
            <ArticleId IdType="pubmed">22078334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmoll, H. J. The role of ifosfamide in testicular cancer. Semin. Oncol. 16, 82–95 (1989).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2649987</ArticleId>
            <ArticleId IdType="pmc">2649987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nichols, C. R. Ifosfamide in the treatment of germ cell tumors. Semin. Oncol. 23, 65–73 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8677452</ArticleId>
            <ArticleId IdType="pmc">8677452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loehrer, P. J. Sr., Einhorn, L. H. &amp; Williams, S. D. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J. Clin. Oncol. 4, 528–536 (1986).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1986.4.4.528</ArticleId>
            <ArticleId IdType="pubmed">3633952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nichols, C. R. et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J. Clin. Oncol. 16, 1287–1293 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1998.16.4.1287</ArticleId>
            <ArticleId IdType="pubmed">9552027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lorch, A. et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J. Clin. Oncol. 29, 2178–2184 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.32.6678</ArticleId>
            <ArticleId IdType="pubmed">21444870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J. Clin. Oncol. 28, 4906–4911 (2010). This is the first publication of the International Prognostic Factors Study Group risk classification system.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.26.8128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pico, J. L. et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann. Oncol. 16, 1152–1159 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdi228</ArticleId>
            <ArticleId IdType="pubmed">15928070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oing, C., Lorch, A. &amp; Bokenmeyer, C. Ongoing clinical trials in testicular cancer: the TIGER trial. Oncol. Res. Treat. 39, 553–556 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000448868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rice, K. R. et al. Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes. J. Urol. 192, 1403–1409 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.juro.2014.05.118</ArticleId>
            <ArticleId IdType="pubmed">24952240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharp, D. S. et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J. Clin. Oncol. 26, 5524–5529 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.15.7453</ArticleId>
            <ArticleId IdType="pubmed">18936477</ArticleId>
            <ArticleId IdType="pmc">2651099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kondagunta, G. V. et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol. 23, 6549–6555 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.19.638</ArticleId>
            <ArticleId IdType="pubmed">16170162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oing, C., Seidel, C., von Amsberg, G., Oechsle, K. &amp; Bokemeyer, C. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments. Expert Opin. Pharmacother. 17, 545–560 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14656566.2016.1127357</ArticleId>
            <ArticleId IdType="pubmed">26630452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adra, N. et al. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience. J. Clin. Oncol. 35, 1096–1102 (2017). This large single-institution study demonstrates that HDCT followed by peripheral blood stem cell transplantation is highly effective in treating patients with relapsed metastatic germ cell tumours.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.69.5395</ArticleId>
            <ArticleId IdType="pubmed">27870561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joly, F. et al. Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J. Clin. Oncol. 20, 73–80 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2002.20.1.73</ArticleId>
            <ArticleId IdType="pubmed">11773156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleer, J., Hoekstra, H. J., Sleijfer, D. T. &amp; Hoekstra-Weebers, J. E. Quality of life of survivors of testicular germ cell cancer: a review of the literature. Support. Care Cancer 12, 476–486 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00520-004-0646-x</ArticleId>
            <ArticleId IdType="pubmed">15179563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahl, A. A., Mykletun, A. &amp; Fossa, S. D. Quality of life in survivors of testicular cancer. Urol. Oncol. 23, 193–200 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.urolonc.2005.03.004</ArticleId>
            <ArticleId IdType="pubmed">15907721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mykletun, A. et al. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J. Clin. Oncol. 23, 3061–3068 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.08.048</ArticleId>
            <ArticleId IdType="pubmed">15860864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efstathiou, E. &amp; Logothetis, C. J. Review of late complications of treatment and late relapse in testicular cancer. J. Natl Compr. Canc. Netw. 4, 1059–1070 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2006.0088</ArticleId>
            <ArticleId IdType="pubmed">17112453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fossa, S. D., Oldenburg, J. &amp; Dahl, A. A. Short- and long-term morbidity after treatment for testicular cancer. BJU Int. 104, 1418–1422 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1464-410X.2009.08869.x</ArticleId>
            <ArticleId IdType="pubmed">19840023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossen, P. B., Pedersen, A. F., Zachariae, R. &amp; von der Maase, H. Health-related quality of life in long-term survivors of testicular cancer. J. Clin. Oncol. 27, 5993–5999 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2008.19.6931</ArticleId>
            <ArticleId IdType="pubmed">19858403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glendenning, J. L. et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 116, 2322–2331 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20225230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vidrine, D. J. et al. The effects of testicular cancer treatment on health-related quality of life. Urology 75, 636–641 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.urology.2009.09.053</ArticleId>
            <ArticleId IdType="pubmed">19963242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilligan, T. Quality of life among testis cancer survivors. Urol. Oncol. 33, 413–419 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.urolonc.2015.05.018</ArticleId>
            <ArticleId IdType="pubmed">26087970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fung, C., Fossa, S. D., Williams, A. &amp; Travis, L. B. Long-term morbidity of testicular cancer treatment. Urol. Clin. North Am. 42, 393–408 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ucl.2015.05.002</ArticleId>
            <ArticleId IdType="pubmed">26216826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerns, S. L. et al. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J. Clin. Oncol. 36, 1505–1512 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.0735</ArticleId>
            <ArticleId IdType="pubmed">29617189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orre, I. J. et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J. Psychosom. Res. 64, 363–371 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpsychores.2008.01.002</ArticleId>
            <ArticleId IdType="pubmed">18374735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eberhard, J. et al. Sexual function in men treated for testicular cancer. J. Sex. Med. 6, 1979–1989 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1743-6109.2009.01298.x</ArticleId>
            <ArticleId IdType="pubmed">19453896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaid, M. A. et al. Clinical and genetic risk factors for adverse metabolic outcomes in North American testicular cancer survivors. J. Natl Compr. Canc. Netw. 16, 257–265 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2017.7046</ArticleId>
            <ArticleId IdType="pubmed">29523664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Carrigan, B. et al. Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study. Intern. Med. J. 44, 813–817 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imj.12500</ArticleId>
            <ArticleId IdType="pubmed">25081047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiechno, P., Demkow, T., Kubiak, K., Sadowska, M. &amp; Kaminska, J. The quality of life and hormonal disturbances in testicular cancer survivors in cisplatin era. Eur. Urol. 52, 1448–1454 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2007.05.012</ArticleId>
            <ArticleId IdType="pubmed">17544206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuinman, M. A. et al. Testicular cancer: a longitudinal pilot study on stress response symptoms and quality of life in couples before and after chemotherapy. Support. Care Cancer 15, 279–286 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00520-006-0119-5</ArticleId>
            <ArticleId IdType="pubmed">16944218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuinman, M. A., Fleer, J., Hoekstra, H. J., Sleijfer, D. T. &amp; Hoekstra-Weebers, J. E. Quality of life and stress response symptoms in long-term and recent spouses of testicular cancer survivors. Eur. J. Cancer 40, 1696–1703 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2004.03.020</ArticleId>
            <ArticleId IdType="pubmed">15251159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weijl, N. I. et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J. Clin. Oncol. 18, 2169–2178 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2000.18.10.2169</ArticleId>
            <ArticleId IdType="pubmed">10811682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore, R. A. et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J. Clin. Oncol. 29, 3466–3473 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2011.35.5669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H. &amp; Francis, C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111, 4902–4907 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2007-10-116327</ArticleId>
            <ArticleId IdType="pubmed">18216292</ArticleId>
            <ArticleId IdType="pmc">18216292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piketty, A. C. et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br. J. Cancer 93, 909–914 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6602791</ArticleId>
            <ArticleId IdType="pubmed">2361657</ArticleId>
            <ArticleId IdType="pmc">2361657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bezan, A. et al. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLOS ONE 12, e0176283 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0176283</ArticleId>
            <ArticleId IdType="pubmed">5400272</ArticleId>
            <ArticleId IdType="pmc">5400272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim, C. et al. Quality of life among testicular cancer survivors: a case-control study in the United States. Qual. Life Res. 20, 1629–1637 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11136-011-9907-6</ArticleId>
            <ArticleId IdType="pubmed">3149776</ArticleId>
            <ArticleId IdType="pmc">3149776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lauritsen, J. et al. Germ cell cancer and multiple relapses: toxicity and survival. J. Clin. Oncol. 33, 3116–3123 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2014.60.1310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Wit, R. Management of germ cell cancer: lessons learned from a national database. J. Clin. Oncol. 33, 3078–3079 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.62.9907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fossa, S. D. et al. Noncancer causes of death in survivors of testicular cancer. J. Natl Cancer Inst. 99, 533–544 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djk111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fung, C. et al. Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J. Clin. Oncol. 33, 3105–3115 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2014.60.3654</ArticleId>
            <ArticleId IdType="pubmed">4582143</ArticleId>
            <ArticleId IdType="pmc">4582143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baniel, J. &amp; Sella, A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin. Surg. Oncol. 17, 263–267 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1098-2388(199912)17:4&lt;263::AID-SSU7&gt;3.0.CO;2-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heidenreich, A., Thuer, D. &amp; Polyakov, S. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur. Urol. 53, 260–272 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2007.10.033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta, A. &amp; Sigman, M. Management of the dry ejaculate: a systematic review of aspermia and retrograde ejaculation. Fertil. Steril. 104, 1074–1081 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2015.09.024</ArticleId>
            <ArticleId IdType="pubmed">26432530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishra, S. I., Scherer, R. W., Snyder, C., Geigle, P. &amp; Gotay, C. Are exercise programs effective for improving health-related quality of life among cancer survivors? A systematic review and meta-analysis. Oncol. Nurs. Forum 41, E326–E342 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1188/14.ONF.E326-E342</ArticleId>
            <ArticleId IdType="pubmed">25355029</ArticleId>
            <ArticleId IdType="pmc">4332787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kvammen, O. et al. Long-term relative survival after diagnosis of testicular germ cell tumor. Cancer Epidemiol. Biomarkers Prev. 25, 773–779 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1055-9965.EPI-15-1153</ArticleId>
            <ArticleId IdType="pubmed">26908435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oldenburg, J. et al. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann. Oncol. 26, 833–838 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdu514</ArticleId>
            <ArticleId IdType="pubmed">25378299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nigam, M., Aschebrook-Kilfoy, B., Shikanov, S. &amp; Eggener, S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J. Urol. 33, 623–631 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00345-014-1361-y</ArticleId>
            <ArticleId IdType="pubmed">25030752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stang, A. et al. Gonadal and extragonadal germ cell tumours in the United States, 1973–2007. Int. J. Androl 35, 616–625 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2605.2011.01245.x</ArticleId>
            <ArticleId IdType="pubmed">22320869</ArticleId>
            <ArticleId IdType="pmc">3631107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen, H. et al. Integrated molecular characterization of testicular germ cell tumors. Cell Rep. 23, 3392–3406 (2018). This is a landmark TCGA study on molecular characterization of testicular cancer.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.05.039</ArticleId>
            <ArticleId IdType="pubmed">29898407</ArticleId>
            <ArticleId IdType="pmc">6075738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman, D. R. et al. Genetic determinants of cisplatin-resistance in advanced germ cell tumors. J. Clin. Oncol. 34, 4000–4007 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.68.7798</ArticleId>
            <ArticleId IdType="pubmed">27646943</ArticleId>
            <ArticleId IdType="pmc">5477828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman, D. R. Treatment options for stage I nonseminoma. J. Clin. Oncol. 32, 3797–3800 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2014.56.8006</ArticleId>
            <ArticleId IdType="pubmed">25366681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P. &amp; Lee, S. S. Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol. Ther. Nucleic Acids 8, 132–143 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omtn.2017.06.005</ArticleId>
            <ArticleId IdType="pubmed">5496203</ArticleId>
            <ArticleId IdType="pmc">5496203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhala, N. et al. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients. Clin. Oncol. 16, 40–47 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0936-6555(03)00166-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01873326 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02582697 (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Beyer, J., Stenning, S., Gerl, A., Fossa, S. &amp; Siegert, W. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann. Oncol. 13, 599–605 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdf112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02375204 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>[No authors listed.] Stat bite: average years of life lost from cancer. J. Natl Cancer Inst. 93, 341 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/93.5.341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oing, C., Seidel, C. &amp; Bokemeyer, C. Therapeutic approaches for refractory germ cell cancer. Expert Rev. Anticancer Ther. 18, 389–397 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14737140.2018.1450630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman, D. R. et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest. New Drugs 28, 523–528 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10637-009-9280-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oechsle, K. et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann. Oncol. 22, 2654–2660 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdr026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Necchi, A. et al. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. Ann. Oncol. 28, 1346–1351 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skonecza, I. et al. Sorafenib monotherapy in patients with inoperable/recurrent germ cell tumors (GCT) refractory to chemotherapy: phase II study. J. Clin. Oncol. 32, 367 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2014.32.4_suppl.367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain, A., Brames, M. J., Vaughn, D. J. &amp; Einhorn, L. H. Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors. Am. J. Clin. Oncol. 37, 450–453 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/COC.0b013e31827de90d</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kollmannsberger, C. et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J. Clin. Oncol. 20, 2031–2037 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2002.08.050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adra, N. et al. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann. Oncol. 29, 209–214 (2018). This is the first reported trial evaluating immune checkpoint inhibitors for treatment of chemoresistant testicular cancer.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03158064 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03081923 (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02689219 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Necchi, A. et al. Brentuximab vedotin in CD30-expressing germ cell tumors after chemotherapy failure. Clin. Genitourin. Cancer 14, 261–264 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clgc.2016.03.020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albany, C. et al. Treatment of CD30-expressing germ cell tumors and sex cord stromal tumors with brentuximab vedotin: identification and report of seven cases. Oncologist 23, 316–323 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2017-0544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02429466 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02478502 (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02115165 (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Wheeler, H. E. et al. Variants in WFS1 and other mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clin. Cancer Res. 23, 3325–3333 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-2809</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
